Soleno Therapeutics files Nasdaq Form 25 to delist common stock

Soleno Therapeutics Inc. filed a Form 25 notifying Nasdaq Stock Market LLC of the removal of its Common Stock from listing and/or registration under Section 12(b) of the Exchange Act.

Rhea-AI Filing Summary

Soleno Therapeutics Inc. filed a Form 25 notifying Nasdaq Stock Market LLC of the removal of its Common Stock from listing and/or registration under Section 12(b) of the Exchange Act. The notification states Nasdaq and the issuer followed the procedures in 17 CFR 240.12d2-2 and that the Exchange has reasonable grounds for the filing.

Insights

Corporate Governance Analyst

Form 25 records a delisting/withdrawal process for the company's common stock.

The filing documents that Nasdaq Stock Market LLC submitted a Form 25 to remove or withdraw registration of Common Stock under Section 12(b). The notice cites compliance with 17 CFR 240.12d2-2 procedural requirements.

Timing and next steps for shareholders (such as final delisting effective date or transfer to OTC quotation) are not included in the excerpt; follow-up filings or exchange notices will provide those specifics.

Key Figures

Commission File Number: 001-36593 Regulatory citation: 17 CFR 240.12d2-2 Exchange: Nasdaq Stock Market LLC +2 more

5 metrics

Commission File Number 001-36593 Form 25 cover

Regulatory citation 17 CFR 240.12d2-2 procedural compliance cited in the notice

Exchange Nasdaq Stock Market LLC Exchange filing the Form 25

Class of securities Common Stock security class being removed

Document header date (expires) March 31, 2018 header expiration line in the excerpt

Key Terms

Form 25, 17 CFR 240.12d2-2, Section 12(b)

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(a)(1)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

Section 12(b) regulatory

"UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Soleno Therapeutics (SLNO) filing a Form 25 mean?

It means Nasdaq submitted a notification to remove or withdraw registration of Soleno's Common Stock under Section 12(b). The filing states procedural compliance with 17 CFR 240.12d2-2, but does not state an effective delisting date.

Who signed the Form 25 for SLNO and which exchange is involved?

The Form 25 is signed on behalf of Nasdaq Stock Market LLC by Tara Petta, AVP. The filing identifies Nasdaq Stock Market LLC as the exchange seeking removal of SLNO Common Stock from listing.

Does the Form 25 state when SLNO shares will stop trading on Nasdaq?

No. The excerpt certifies compliance with delisting procedures but does not provide an effective date or schedule. Further exchange notices or subsequent filings would state the exact effective date for removal.

Will Soleno Therapeutics (SLNO) still be a registered issuer after this Form 25?

The filing notifies removal of the class of securities from Nasdaq listing and/or registration under Section 12(b). It does not describe post-removal registration status or alternative quotation venues; subsequent disclosures would clarify next steps.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 09:07 AM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36593

Issuer:	SOLENO THERAPEUTICS INC
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	203 Redwood Shores Parkway
	Suite 500
	Redwood City	CALIFORNIA	94065
Telephone number:					650-213-8444

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-18	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.